drugset / Trial / NCT04204603

A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate

NCT04204603 ↗

Phase 2 Completed 122 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the effects of CKD-506 on signs and symptoms of RA in subjects with moderate-to-severe RA who are inadequate responders to methotrexate.

Timeline

Start
2018-11-30
Primary completion
2019-09-30
Completion
2019-10-29

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-506 Unknown — Oral

Indications